Concepedia
Statistics
Publications
12
Citations
498
H-Index
10
Active since
2003
Affiliations
National Cancer Institute(Current)
National Institutes of Health
Center for Cancer Research
Herb Kotz is an author at National Cancer Institute specializing in cancer pharmacology, pharmacology, and medicine.
Publications per year
2003–2015
Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days
Jame Abraham, Manish Agrawal, Susan Bakke et al. · Journal of Clinical Oncology · 2003 · 136 citations
Medicine, Pharmacokinetics, Pharmacology +12
A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
Sen Hong Zhuang, Manish Agrawal, Maureen Edgerly et al. · Cancer · 2005 · 81 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +10
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Gisele Sarosy, Christina M. Annunziata, Nilofer S. Azad et al. · British Journal of Cancer · 2010 · 66 citations · Full text
Pharmacy, Oncology, Pharmacology +13
A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Hui Huang, Michael E. Menefee, Maureen Edgerly et al. · Clinical Cancer Research · 2010 · 42 citations · Full text
Medicine, Oncology, Pharmacology +12
Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab
Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski et al. · Journal of Clinical Oncology · 2006 · 42 citations
Pharmacy, Oncology, Pharmacology +17
1–5 of 12